Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Canc J Clin. 2009, 59: 225-249. 10.3322/caac.20006.
Article
Google Scholar
Cheng L, Montironi R, Davidson DD, Lopez-Beltran A: Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol. 2009, 22 (Suppl 2): S70-S95.
Article
PubMed
Google Scholar
Casadio V, Molinari C, Calistri D, Tebaldi M, Gunelli R, Serra L, Falcini F, Zingaretti C, Silvestrini R, Amadori D, Zoli W: DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach. J Exp Clin Canc Res. 2013, 32: 94-10.1186/1756-9966-32-94.
Article
Google Scholar
Holmäng S, Hedelin H, Anderström C, Johansson SL: The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol. 1995, 153: 1823-1826. 10.1016/S0022-5347(01)67321-X.
Article
PubMed
Google Scholar
Sengupta S, Blute ML: The management of superficial transitional cell carcinoma of the bladder. Urology. 2006, 67 (Suppl 1): 48-54.
Article
PubMed
Google Scholar
Armstrong AB, Wang M, Eble JN, MacLennan GT, Montironi R, Tan PH, Lopez-Beltran A, Zhang S, Baldridge LA, Spartz H, Cheng L: TP53 mutational analysis supports monoclonal origin of biphasic sarcomatoid urothelial carcinoma (carcinosarcoma) of the urinary bladder. Mod Pathol. 2009, 22: 113-118. 10.1038/modpathol.2008.176.
Article
CAS
PubMed
Google Scholar
Takahashi K, Yamamura H, Awata N, Takahashi K: Role of calponin in the generation and differentiation of blood vessels - increased bone formation in mice lacking smooth muscle calponin. Clin Calcium. 2001, 11: 450-454.
CAS
PubMed
Google Scholar
Sone M, Takahashi K, Totsune K, Murakami O, Arihara Z, Satoh F, Mouri T, Shibahara S: Expression of endothelin-1 and endothelin receptors in cultured human glioblastoma cells. J Cardiovasc Pharmacol. 2000, 36 (Suppl 1): S390-S392.
Article
CAS
PubMed
Google Scholar
Lovat F, Bitto A, Xu SQ, Fassan M, Goldoni S, Metalli D, Wubah V, McCue P, Serrero G, Gomella LG, Baffa R, Iozzo RV, Morrione A: Proepithelin is an autocrine growth factor for bladder cancer. Carcinogenesis. 2009, 30: 861-868. 10.1093/carcin/bgp050.
Article
PubMed Central
CAS
PubMed
Google Scholar
Kong C, Zhu Y, Liu D, Yu M, Li S, Li Z, Sun Z, Liu G: Role of protein kinase C-alpha in superficial bladder carcinoma recurrence. Urology. 2005, 65: 1228-1232. 10.1016/j.urology.2005.01.007.
Article
PubMed
Google Scholar
Sitnikova L, Mendese G, Liu Q, Woda BA, Lu D, Dresser K, Mohanty S, Rock KL, Jiang Z: IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res. 2008, 14: 1701-1706. 10.1158/1078-0432.CCR-07-2039.
Article
CAS
PubMed
Google Scholar
Grieco P, Franco R, Bozzuto G, Toccacieli L, Sgambato A, Marra M, Zappavigna S, Migaldi M, Rossi G, Striano S, Marra L, Gallo L, Cittadini A, Botti G, Novellino E, Molinari A, Budillon A, Caraglia M: Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells. J Cell Biochem. 2011, 112: 341-353. 10.1002/jcb.22933.
Article
CAS
PubMed
Google Scholar
Wang H, Dong K, Xue X, Feng P, Wang X: Elevated expression of urotensin II and its receptor in diethylnitrosamine-mediated precancerous lesions in rat liver. Peptides. 2011, 32: 382-387. 10.1016/j.peptides.2010.10.032.
Article
PubMed
Google Scholar
Takahashi K, Totsune K, Murakami O, Shibahara S: Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adrenocortical carcinoma cells. Peptides. 2001, 22: 1175-1179. 10.1016/S0196-9781(01)00441-7.
Article
CAS
PubMed
Google Scholar
Takahashi K, Totsune K, Murakami O, Arihara Z, Noshiro T, Hayashi Y, Shibahara S: Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II. Peptides. 2003, 24: 301-306. 10.1016/S0196-9781(03)00039-1.
Article
CAS
PubMed
Google Scholar
Kristof AS, You Z, Han YS, Giaid A: Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis. Peptides. 2010, 31: 1511-1516. 10.1016/j.peptides.2010.04.017.
Article
PubMed Central
CAS
PubMed
Google Scholar
Eble JN, Sauter G, Epstein JI, Sesterhenn IA: World Organization Classification of tumors. Tumors of the Urinary System and Genital Organs Pathology and Genetics. 2004, Lyon: IARC Press
Google Scholar
Grieco P, Carotenuto A, Campiglia P, Gomez-Monterrey I, Auriemma L, Sala M, Marcozzi C, d'Emmanuele di Villa Bianca R, Brancaccio D, Rovero P, Santicioli P, Meini S, Maggi CA, Novellino E: New insight into the binding mode of peptide ligands at Urotensin-II receptor: structure-activity relationships study on P5U and urantide. J Med Chem. 2009, 52: 3927-3940. 10.1021/jm900148c.
Article
CAS
PubMed
Google Scholar
Marra M, Santini D, Meo G, Vincenzi B, Zappavigna S, Baldi A, Rosolowski M, Tonini G, Loeffler M, Lupu R, Addeo SR, Abbruzzese A, Budillon A, Caraglia M: Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. Int J Cancer. 2009, 125: 2004-2013. 10.1002/ijc.24648.
Article
CAS
PubMed
Google Scholar
Colone M, Calcabrini A, Toccacieli L, Bozzuto G, Stringaro A, Gentile M, Cianfriglia M, Ciervo A, Caraglia M, Budillon A, Meo G, Arancia G, Molinari A: The multidrug transporter P-glycoprotein: a mediator of melanoma invasion?. J Invest Dermatol. 2008, 128: 957-971. 10.1038/sj.jid.5701082.
Article
CAS
PubMed
Google Scholar
Cookson MS, Herr HW, Zhang Z, Soloway S, Sogani PC, Fair WR: The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol. 1997, 158: 62-67. 10.1097/00005392-199707000-00017.
Article
CAS
PubMed
Google Scholar
Angulo JC, Lopez JI, Flores N, Toledo JD: The value of tumour spread, grading, growth pattern as morphological predictive parameters in bladder carcinoma. A critical revision of the 1987 TNM classification. J Cancer Res Clin Oncol. 1993, 119: 578-593. 10.1007/BF01372721.
Article
CAS
PubMed
Google Scholar
Smith JA, Labasky RF, Cockett ATK, Fracchia JA, Montie JE, Rowland RG: Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). J Urol. 1999, 162: 1697-1701. 10.1016/S0022-5347(05)68208-0.
Article
PubMed
Google Scholar
Murphy WM, Takezawa K, Maruniak NA: Interobserver discrepancy using the 1998 World Health Organization/International Society of Urologic Pathology classification of urothelial neoplasms: practical choices for patient care. J Urol. 2002, 168: 968-972. 10.1016/S0022-5347(05)64553-3.
Article
PubMed
Google Scholar
Budman LI, Kassouf W, Steinberg JR: Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J. 2008, 2: 212-221.
PubMed Central
PubMed
Google Scholar
Alvarez A, Lokeshwar VB: Bladder cancer biomarkers: current developments and future implementation. Curr Opin Urol. 2007, 17: 341-346. 10.1097/MOU.0b013e3282c8c72b.
Article
PubMed
Google Scholar
Merlino F, Di Maro S, Munaim Yousif A, Caraglia M, Grieco P: Urotensin-II ligands: an overview from peptide to nonpeptide structures. J Amino Acids. 2013, DOI: 10.1155/2013/979016
Google Scholar
Morimoto R, Satoh F, Murakami O, Totsune K, Arai Y, Suzuki T, Sasano H, Ito S, Takahashi K: Immunolocalization of urotensin II and its receptor in human adrenal tumors and attached non-neoplastic adrenal tissues. Peptides. 2008, 29: 873-880. 10.1016/j.peptides.2007.06.025.
Article
CAS
PubMed
Google Scholar
Douglas SA, Ohlstein EH: Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med. 2000, 10: 229-237. 10.1016/S1050-1738(00)00069-4.
Article
CAS
PubMed
Google Scholar
Gardiner SM, March JE, Kemp PA, Davenport AP, Bennett T: Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol. 2001, 132: 1625-1629. 10.1038/sj.bjp.0704051.
Article
PubMed Central
CAS
PubMed
Google Scholar
Camarda V, Song W, Marzola E, Spagnol M, Guerrini R, Salvadori S, Regoli D, Thompson JP, Rowbotham DJ, Behm DJ, Douglas SA, Calo' G, Lambert DG: Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. Eur J Pharmacol. 2004, 498: 83-86. 10.1016/j.ejphar.2004.07.089.
Article
CAS
PubMed
Google Scholar